Literature DB >> 19937679

Alanine aminotransferase: is it healthy to be "normal"?

D Robert Dufour.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19937679     DOI： 10.1002/hep.23358

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  5 in total

1.  Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels.

Authors:  Dong Hyun Sinn; Geum-Youn Gwak; Jae-Uk Shin; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

2.  A Retrospective and Multicenter Study on COVID-19 in Inner Mongolia: Evaluating the Influence of Sampling Locations on Nucleic Acid Test and the Dynamics of Clinical and Prognostic Indexes.

Authors:  Lan Yu; Ailan Wang; Tianbao Li; Wen Jin; Geng Tian; Chunmei Yun; Fei Gao; Xiuzhen Fan; Huimin Wang; Huajun Zhang; Dejun Sun
Journal:  Front Med (Lausanne)       Date:  2022-03-30

3.  Exploration of Biomarkers for Amoxicillin/Clavulanate-Induced Liver Injury: Multi-Omics Approaches.

Authors:  J Lee; S C Ji; B Kim; S Yi; K H Shin; J Y Cho; K S Lim; S H Lee; S H Yoon; J Y Chung; K S Yu; H S Park; S H Kim; I J Jang
Journal:  Clin Transl Sci       Date:  2016-10-26       Impact factor: 4.689

4.  Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels.

Authors:  Lingmei Wang; Jiao Li; Kai Yang; Hao Zhang; Qin Wang; Xiongwen Lv; Shihe Guan
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

Review 5.  Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.

Authors:  William R Treem; Melissa Palmer; Isabelle Lonjon-Domanec; Daniel Seekins; Lara Dimick-Santos; Mark I Avigan; John F Marcinak; Ajit Dash; Arie Regev; Eric Maller; Meenal Patwardhan; James H Lewis; Don C Rockey; Adrian M Di Bisceglie; James W Freston; Raul J Andrade; Naga Chalasani
Journal:  Drug Saf       Date:  2020-11-03       Impact factor: 5.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.